NovoCure
NVCR
239 hedge funds and large institutions have $2.73B invested in NovoCure in 2024 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 65 increasing their positions, 78 reducing their positions, and 37 closing their positions.
289% more call options, than puts
Call options by funds: $68.8M | Put options by funds: $17.7M
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
88% more capital invested
Capital invested by funds: $1.45B → $2.73B (+$1.28B)
46% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 37
6% more funds holding
Funds holding: 225 → 239 (+14)
1.19% less ownership
Funds ownership: 85.82% → 84.63% (-1.2%)
17% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 78
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$58M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$20.1M |
| 3 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$14.5M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$11.6M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NA
Nordwand Advisors
Radnor,
Pennsylvania
|
-$57.5M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$23.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$10.8M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$10.5M |
NVCR Hedge Fund Activity: Q4 2024 in Review
239 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q4 2024, worth a combined $2.73B — up 88% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new NVCR positions and 37 closed out — a net gain of 17 holders — while 65 added to existing stakes and 78 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $58M. The largest seller was Nordwand Advisors, cutting an estimated $57.5M.
- 239 institutional investors held NovoCure (NVCR) as of Q4 2024, up from 225 in Q3 2024.
- Funds reported $2.73B of NovoCure stock for Q4 2024, up 88% quarter-over-quarter.
- 54 funds opened new NovoCure positions in Q4 2024 and 37 closed out, a net change of +17 holders.
- The largest NovoCure buyer in Q4 2024 was Soleus Capital Management, an estimated $58M added.
- The largest NovoCure seller in Q4 2024 was Nordwand Advisors, an estimated $57.5M sold.
Based on aggregated 13F filings for Q4 2024.